Humira 40 mg solution for injection in pre-filled syringeXELJANZ 1 mg/mL oral solutionORENCIA 87.5 mg solution for injection in pre-filled syringeORENCIA 125 mg solution for injection in pre-filled syringeTyenne 162mg/0.9ml solution for injection in pre-filled syringeORENCIA 50 mg solution for injection in pre-filled syringeEnbrel 50 mg solution for injection in pre-filled syringeXELJANZ 5 mg film-coated tabletsHumira 20 mg solution for injection in pre-filled syringeEnbrel 25 mg solution for injection in pre-filled syringe
Eligibility
Age group
0-17 years
Sex
Female, Male
Primary endpoint
Minimal disease activity (MiDA) at Month 6 as assessed by the cJADAS10 less than or equal to 5
Endpoint detail
PROMIS® pain interference at Month 6, PROMIS® fatigue at Month 6, PROMIS® mobility at Month 6, Change in arthritis disease activity (cJADAS10 and JIA American College of Rheumatology Pediatric 70 [ACR 70]) at Month 6, Change in arthritis disease activity (cJADAS10) at Month 12
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.